Eli Lilly (LLY)

The global market for obesity drugs is soaring, yet Lilly has a dominant market share.

IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio.

FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.

Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced pressure.

There are other reasons to pay attention to Viking Therapeutics.

PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost option.

CNBC's Mad Money Lightning Round: Cramer says Astera Labs (ALAB) is a buy, but doesn't care for Rigetti Computing (RGTI). Eli Lilly (LLY) is a classic own, don't trade. MakeMyTrip (MMYT) coverage initiated with Buy rating.

But is that performance sustainable?

They may profit from the rapidly growing GLP-1 market in very different ways.

FBT delivered 48.5% returns over one year but carries a 0.55% expense ratio and experiences greater volatility. XLV offers lower costs, with an 0.08% expense ratio, as well as broader diversification across 60 healthcare stocks.

Lilly's pipeline is on track to pick up a handful of interesting new programs.

Will this pharma company become a new leader in the weight loss market?

Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.

The market has hit new records this year, but it isn't the "Magnificent Seven" stocks that are leading the way.

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Quadrupling your money in four years is an incredible rate of return.

The company isn't resting on its laurels.

Can growth stocks maintain their momentum, or is it time to diversify?

Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.

VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors.

The Schwab U.S. Dividend Equity ETF has the superior selection strategy, while the Vanguard Dividend Appreciation ETF has a bigger growth and tech tilt.

State Street's fund charges just 0.08% annually versus 0.38% for iShares, but the broader portfolio offers 100 holdings versus 60.

State Street's concentrated 60-stock approach outpaced Fidelity's broader 365-holding fund over five years, though both charge identical 0.08% fees.

A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits...